UNSPSC 51401509: Meclonazepam

This classification denotes a benzodiazepine with the molecular formula C16H12ClN3O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier RN43209SMA, chemically known as 5-(2-chlorophenyl)-1,3-dihydro-3-methyl-7-nitro-2h-1,4-benzodiazepin-2-one but generally known as meclonazepam, which bears US NIH Compound Identifier 93364. European Medicines Agency schedules Meclonazepam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08680MIG.

UNSPSC 51401509 Meclonazepam is a Commodity code that in recent state and local procurement activity covers pharmaceutical products supplied through state health and human services channels, though the code's nominal substance name does not consistently match the actual scope of opportunities posted under it. State and local governments soliciting under this code are purchasing naloxone and drug deactivation systems for community health initiatives, generic multi-source pharmaceuticals and over-the-counter products through cooperative purchasing alliances, and evaluating direct-to-manufacturer prescription fulfillment models. The issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS), and multistate cooperative purchasing organizations (Minnesota Multistate Cooperative Purchasing Alliance). Work solicited ranges from annual procurement of finished naloxone units and drug deactivation systems with quarterly delivery schedules to establishment of statewide or multi-state master agreements for pharmaceutical supply chains managed through authorized wholesalers.

Recent activity spans Florida, Texas, and Minnesota through cooperative vehicles and direct county procurement. Seminole County issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with a July 26, 2023 response deadline and a two-year initial term with one-year renewal option. The Texas HHS Commission released Request for Information HHS0017013 in April 2026 to evaluate vendor capabilities for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager arrangements. The Minnesota Department of Administration's Office of State Procurement issued an RFP through MMCAP in January 2026 with a March 26, 2026 response deadline to establish multiple contracts for generic pharmaceuticals and OTC products, requiring vendor compliance with cGMP and Drug Supply Chain Security Act standards, relationships with at least two of three authorized wholesalers, and a 3 percent administrative fee, with contract awards effective July 1, 2026.